Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia

The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet